The HinduLean L·
Generics maker Laurus Lab’s net profit more than doubles in Q1 on strong CDMO business growth
Within CDMO, small molecules segment increased 69%, driven by growth in late-stage clinical and commercial API supplies.
Read at The Hindu →


